Recent Updates
Recently added Catalysts
ARGX Positive Sentiment

argenx to Present at Upcoming Investor Conferences

Key Takeaway: argenx announced its participation in two upcoming investor conferences in September 2026. The management team will engage in fireside chats at the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Live webcasts of these presentations will be available on the company's website.
Price reaction · baseline $1031.66 (2026-08-31 close) · hit pre-market · 1 other ARGX headline(s) in the window, move may be shared
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Management team is actively engaging with investors.
  • Participation in notable healthcare conferences enhances visibility.
  • Webcasts provide accessible information for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis

Full Press Release Details

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
• Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.
• Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY.
A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Investors:

Frequently Asked Questions

When will argenx participate in investor conferences?

argenx will participate in investor conferences on September 8 and 14, 2026.

Where can I watch the presentations?

Live webcasts of the presentations will be available on the argenx website.

What is the focus of argenx's research?

argenx focuses on developing treatments for severe autoimmune diseases.

What is the significance of FcRn blockers?

FcRn blockers are important for treating various serious autoimmune diseases.

Last updated: Sep 1, 2026